Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety.
about
Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitisAzathioprine or 6-mercaptopurine for maintenance of remission in Crohn's diseaseAzathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitisAzathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitisNodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprineOptimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel diseaseTherapeutic drug monitoring in inflammatory bowel diseaseThiopurine monitoring in children with inflammatory bowel disease: a systematic reviewReview article: the management of autoimmune hepatitis beyond consensus guidelinesImputation of TPMT defective alleles for the identification of patients with high-risk phenotypesPharmacogenetics in inflammatory bowel disease: understanding treatment response and personalizing therapeutic strategiesClassification and management of refractory coeliac diseaseRoutine use of thiopurines in maintaining remission in pediatric Crohn's disease.Current status of thiopurine analogues in the treatment in Crohn's disease.Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and SpainStudy of drug metabolism by xanthine oxidase.The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease.A small molecule screening to detect potential therapeutic targets in human podocytes.The use of medications for inflammatory bowel disease during pregnancy and nursing.The long-term risk of continuous immunosuppression using thioguanides in inflammatory bowel diseaseThe utility of thiopurine methyltransferase enzyme testing in inflammatory bowel disease.Clinical application of pharmacogenetics in gastrointestinal diseases.Update in the treatment of paediatric ulcerative colitis.Drug safety in Crohn's disease therapy.Inflammatory bowel disease and pregnancy: evidence, uncertainty and patient decision-makingAre we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease.The impact of thiopurines on surgical outcomes in inflammatory bowel disease: do they make a difference?Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease.Specific considerations in the treatment of pediatric inflammatory bowel disease.Hepatic inflammation and progressive liver fibrosis in chronic liver disease.Use of immunomodulators and biologic therapies in children with inflammatory bowel disease.Immunomodulators for all patients with inflammatory bowel disease?Pediatric ulcerative colitis: current treatment approaches including role of infliximab.Drug choices in autoimmune hepatitis: part B--Nonsteroids.Infliximab for the treatment of pediatric ulcerative colitis.Allopurinol enhanced thiopurine treatment for inflammatory bowel disease: safety considerations and guidelines for use.Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD.Thiopurine-induced pancreatitis in inflammatory bowel diseases.Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease.Thiopurine metabolite testing in inflammatory bowel disease.
P2860
Q24185761-3ED1E3D8-B929-442D-AEAD-2DA0B5CD6238Q24186291-F8F3DDF9-FCC5-43FE-B43A-18DA0B7B44CCQ24200757-77C81985-A0BA-4CEB-A05C-C7918523B51CQ24243219-21DDAD61-592B-4856-867B-7D3EE4CA9B88Q24564758-0A7D6943-8283-45B9-AB88-124E61606718Q24631869-ACB549E3-4EA4-4551-8CE9-288E3912DD15Q26852729-2831AD2A-2C9F-4072-9E9A-FCDA09F5BC6FQ26859122-287B1868-AC5D-43C0-81DF-7010B989D4E6Q26864272-743CA0C1-D8A1-4E85-B89F-F96708580726Q33633953-06211493-30B2-4631-8A29-5FAB84792F53Q33758469-E7428C27-D211-42D7-AE83-1628FB7FBBC9Q33817225-FD080A95-C0F6-4430-A86B-B096E3331EAFQ33958703-9CD575AE-64C7-4C35-AFE0-64E8847CDAD7Q34235370-B951791E-B704-43C3-9F13-664B8F0A501AQ34326911-F780D373-00FB-4AC2-81D0-F1E3AA33967FQ35934029-9D92AB26-AB25-48F3-97A1-99DE2D93F1F2Q36026672-DEE9A2EE-0005-4056-9D99-CED92864EF90Q36168378-DB5FFE42-2463-4849-A9D6-382AF1DC81EBQ36249913-C001B2E6-12DB-4533-8DBC-3785FB3D21E5Q36443655-B8DF6E95-98C9-4EA6-8C41-1E430255F45CQ36534663-91DECCCC-4FDF-490D-9E0C-3C4333F9A390Q36613862-B022631A-3A4F-4739-A97D-084B671164ECQ36613876-828ACBD8-8ACF-4C01-84F2-F9541C4170CCQ37073426-AC769CDB-61DC-41E4-88E3-65EB2503CD5FQ37224385-ABBE340F-8E28-4836-A159-1F03D9BF3C42Q37276962-24F0FAED-BCF7-45D6-87C9-3A540BA50418Q37277894-EA10AACE-C853-46B7-907C-7748FF003C25Q37316667-E3940F4D-9574-4774-BBEC-0BF38D9C1110Q37345918-E475C02E-1DD1-4BC0-8EE5-BD264375346EQ37629675-8AC78BFE-7DCA-4F05-AA12-770CF4FA9C96Q37769253-CDD95E23-D037-4C41-9C49-006C2546B228Q37823320-F21955C6-19F1-4F9B-97DC-9F73AFC8E83AQ38022238-24651722-6DE8-40D9-BE7A-02713AE1A944Q38051706-A9CFFC0B-50B9-4568-85ED-D91B0C7CAA07Q38067127-95CD8873-EBB4-4A9C-8D8E-F1F115F07B6EQ38179509-FC846103-80B6-4FB6-B419-A2B0B307AFD0Q38253469-5E18B6FD-77C1-4A5B-9AC7-EBEF5EA83D45Q38286123-3FAD3B2C-F4DF-4FAE-A410-DE75DCB8313BQ38417177-23D36AB2-1DEC-479A-AA85-7905366506B2Q38618602-53237CC3-E94B-4D6C-A883-19B76C6EEC79
P2860
Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Azathioprine, 6-mercaptopurine ...... acology, efficacy, and safety.
@ast
Azathioprine, 6-mercaptopurine ...... acology, efficacy, and safety.
@en
type
label
Azathioprine, 6-mercaptopurine ...... acology, efficacy, and safety.
@ast
Azathioprine, 6-mercaptopurine ...... acology, efficacy, and safety.
@en
prefLabel
Azathioprine, 6-mercaptopurine ...... acology, efficacy, and safety.
@ast
Azathioprine, 6-mercaptopurine ...... acology, efficacy, and safety.
@en
P1476
Azathioprine, 6-mercaptopurine ...... acology, efficacy, and safety.
@en
P2093
Marla C Dubinsky
P304
P356
10.1016/S1542-3565(04)00344-1
P407
P577
2004-09-01T00:00:00Z